Cellyan Biotechnology Secures Nasdaq Extension to January 2027 for $1 Bid Price Compliance; Reverse Split Under Consideration
HKPD sits 69% above its 52-week low of $0.318 on elevated volume (3.1× avg).
Summary
Nasdaq granted Cellyan Biotechnology an additional 180 days, until January 11, 2027, to regain compliance with the $1.00 minimum bid price. The company may effect a reverse stock split to meet the requirement. Stock currently trades at $0.5374.
Key Events · Legal and Risk Events · HKPD
-
Nasdaq Extension Granted
Nasdaq granted an additional 180-day compliance period, extending the deadline to January 11, 2027, for the company to regain a $1.00 minimum closing bid price.
-
Reverse Split Contemplated
To cure the bid price deficiency, the company stated it may effect a reverse share split—a move that could mechanically raise the share price but often leads to further declines.
-
Current Price Far Below Threshold
At $0.5374, the stock needs a near-doubling of its share price or a reverse split to meet the $1.00 requirement, highlighting the severity of the compliance challenge.
-
Delisting Risk Remains
If compliance is not regained by January 11, 2027, the shares could be delisted from Nasdaq, severely reducing liquidity and investor access.
Analysis · HKPD · Trade & Services
A critical 180-day extension from Nasdaq pushes Cellyan Biotechnology's deadline to regain the $1.00 minimum bid price to January 11, 2027. With the stock trading at just $0.5374—well below the threshold—the company has explicitly stated it may execute a reverse stock split to cure the deficiency. This is a high-stakes compliance event: failure to regain compliance would lead to delisting, severely impairing liquidity and investor confidence. While the extension buys time, the likely path to compliance requires a reverse split that could further pressure the stock. Adding to the risk, the filing references an existing $200M shelf registration, introducing a dilution overhang.
At the time of this filing, HKPD was trading at $0.54 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $4.7M. The 52-week trading range was $0.32 to $2.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.